EMPRESS

GIREDESTRANT (GDC-9545) OR TAMOXIFEN IN ER+/HER2- Ki67≥10% EARLY BREAST CANCER

CLINICAL TRIAL DETAILS

THE PRIMARY OBJECTIVE IS TO ASSESS CHANGES IN TUMOR CELL PROLIFERATION AS MEASURED BY KI67 EXPRESSION BETWEEN BASELINE AND POST-TREATMENT TUMOR BIOPSY SAMPLES BY CENTRAL ASSESSMENT IN PATIENTS WITH CENTRALLY CONFIRMED KI67>10% IN GIREDESTRANT VS. TAMOXIFEN. IN ADDITION, THE STUDY WILL MEASURE COMPLETE CELL CYCLE ARREST, ANALYZE CHANGES IN ER AND PGR LEVELS, COMPLETE MOLECULAR PROFILING USING HTG, AND EVALUATE TOXICITY.

EMPRESS AT CLINICALTRIALS.GOV

COUNTRY

STATUS

TUMOR TYPE

PHASE

SITES

ER+/HER2- Ki67≥10% Early Breast Cancer

Spain, France

Closing

TRIAL OVERVIEW

PRESS RELEASE

2025 Press Release

SCIENTIFIC IMPACT

ESMO 2025 presentation

ESMO 2025 lay language summary

BLOG ARTICLES RELATED

-----

TRIAL SITES

Instituto Valenciano de Ocología (Spain) Hospital Clínic i Provincial de Barcelona (Spain) Hospital Clínico Universitario de Valencia (Spain) Hospital Arnau de Vilanova de Valencia (Spain) Hospital General Universitario Dr. Balmis (Spain) Hospital Universitari Dexeus (Spain) Hospital Universitari San Joan de Reus (Spain) Hospital Universitario de Navarra (CUN) (Spain) Hospital Universitario de Basurto (Spain) Institut Català d’ Oncologia Badalona (Spain) Hospital Ruber Internacional (Spain) Hospital Universitario Ramón y Cajal (Spain) Hospital Universitario de León (Spain) Hospital Europeen Georges Pompidou (France) Hôpital Tenon AP-HP (France)

Dr. Cortes and Dr. Llombart PHERain interview

Beyond Chemotherapy

Dr. Vanes Quiroga

Dr. Sofia Braga

Dr. Silvi Antolín

Dr. Escrivá de Romaní

Dr. Philipp Aftimos

Dr. Manuel Ruiz

Prof. Daniele Generali PHEGain interview

Dr. Jacques Medioni

Dr. Dunca Wheatley